Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - Pharmacy News - February 23, 2017

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
2/23/17 - Finch Therapeutics Announces Strategic Collaboration with OpenBiome to Develop Microbiome Therapies for FDA Approval
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration in recurrent C. difficile infections. â??OpenBiome has transformed the standard of care for C. diffici
2/23/17 - IDC Receives FDA Approval for Innovative DR Imaging Devices
Calgary, Alberta- Imaging Dynamics Company Ltd. is pleased to announce that it received notification today that the United States Food and Drug Administration has granted Market Clearance approval for its new Digital Radiography product line- Aquarius 8600 1717 TC and Aquarius 8600 1417 TC. These products utilize and integrate into IDCâ?? s proprie
2/23/17 - Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz New Animal Drug Application
By a News Reporter-Staff News Editor at Politics& Government Week--- Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announced it has received a technical section complete letter for effectiveness from the U.S. Richard Chin, CEO of KindredBio, stated, "This is a major milestone for KindredBi
2/23/17 - Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
--Novartis today announced that the US Food and Drug Administration accepted the Company's supplemental New Drug Application for filing, and granted Priority Review for the expanded use of Zykadia ® as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase- positive as detected by
We initially received U.S. Food and Drug Administration approval for Optune in 2011 for use as a monotherapy treatment for adult patients with GBM following confirmed recurrence after chemotherapy. In November 2014, our phase 3 pivotal trial of Optune in combination with chemotherapy for patients with newly diagnosed GBM met its endpoints after a..
2/23/17 - U.S. FDA Approves Increase in Number of Clinical Sites for E-QUREâ??s Pivotal Trial of BST Device for the Treatment of Chronic Wound Care
E-QURE Corp., a leader in medical devices for the treatment of advanced wound care, announced today that it has received approval from the U.S. Food and Drug Administration to conduct its pivotal trial for the Company's patented Bio-electrical Signal Therapy Device in the treatment of chronic wound care as a staged study, potentially shortening the

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement